{"name":"Rib-X Pharmaceuticals","permalink":"rib-x-pharmaceuticals","crunchbase_url":"http://www.crunchbase.com/company/rib-x-pharmaceuticals","homepage_url":"http://www.rib-x.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"info@rib-x.com","phone_number":"203.624.5606","description":"antibiotic designer","created_at":"Fri Apr 17 16:17:05 UTC 2009","updated_at":"Fri Nov 30 06:22:39 UTC 2012","overview":"<p>Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics.</p>","image":{"available_sizes":[[[150,49],"assets/images/resized/0004/1688/41688v1-max-150x150.png"],[[250,82],"assets/images/resized/0004/1688/41688v1-max-250x250.png"],[[282,93],"assets/images/resized/0004/1688/41688v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[],"competitions":[],"providerships":[],"total_money_raised":"$116M","funding_rounds":[{"round_code":"unattributed","source_url":"http://www.rib-x.com/news_and_events/release_2009_01_26","source_description":"Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing","raised_amount":25000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":1,"funded_day":25,"investments":[{"company":null,"financial_org":{"name":"Warburg Pincus","permalink":"warburg-pincus","image":{"available_sizes":[[[150,50],"assets/images/resized/0001/9008/19008v1-max-150x150.png"],[[250,83],"assets/images/resized/0001/9008/19008v1-max-250x250.png"],[[413,138],"assets/images/resized/0001/9008/19008v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"ABS Ventures","permalink":"abs-ventures","image":{"available_sizes":[[[150,57],"assets/images/resized/0001/0971/10971v1-max-150x150.jpg"],[[182,70],"assets/images/resized/0001/0971/10971v1-max-250x250.jpg"],[[182,70],"assets/images/resized/0001/0971/10971v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Axiom Ventures","permalink":"axiom-ventures","image":{"available_sizes":[[[150,47],"assets/images/resized/0004/7195/47195v1-max-150x150.jpg"],[[193,61],"assets/images/resized/0004/7195/47195v1-max-250x250.jpg"],[[193,61],"assets/images/resized/0004/7195/47195v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"EuclidSR Partners","permalink":"euclidsr-partners","image":null},"person":null},{"company":null,"financial_org":{"name":"MedImmune Ventures","permalink":"medimmune-ventures","image":{"available_sizes":[[[150,34],"assets/images/resized/0004/9449/49449v1-max-150x150.jpg"],[[183,42],"assets/images/resized/0004/9449/49449v1-max-250x250.jpg"],[[183,42],"assets/images/resized/0004/9449/49449v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Oxford Bioscience Partners","permalink":"oxford-bioscience-partners","image":{"available_sizes":[[[150,36],"assets/images/resized/0005/5118/55118v1-max-150x150.jpg"],[[250,61],"assets/images/resized/0005/5118/55118v1-max-250x250.jpg"],[[408,100],"assets/images/resized/0005/5118/55118v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"S.R. One","permalink":"s-r-one","image":{"available_sizes":[[[150,54],"assets/images/resized/0005/5107/55107v2-max-150x150.jpg"],[[205,74],"assets/images/resized/0005/5107/55107v2-max-250x250.jpg"],[[205,74],"assets/images/resized/0005/5107/55107v2-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Vox Equity Partners I","permalink":"vox-equity-partners-i","image":null},"person":null}]},{"round_code":"unattributed","source_url":"http://www.rib-x.com/news_and_events/release_2011_01_11","source_description":"Rib-X Pharmaceuticals Raises $20 Million to Advance its Industry-Leading Antibiotics Pipeline","raised_amount":20000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":1,"funded_day":11,"investments":[{"company":null,"financial_org":{"name":"Warburg Pincus","permalink":"warburg-pincus","image":{"available_sizes":[[[150,50],"assets/images/resized/0001/9008/19008v1-max-150x150.png"],[[250,83],"assets/images/resized/0001/9008/19008v1-max-250x250.png"],[[413,138],"assets/images/resized/0001/9008/19008v1-max-450x450.png"]],"attribution":null}},"person":null}]},{"round_code":"unattributed","source_url":"http://www.masshightech.com/stories/2012/02/06/daily12-Rib-X-lands-3M-milestone-pay-from-Sanofi-deal.html","source_description":"Rib-X lands $3M milestone pay from Sanofi deal","raised_amount":3000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":2,"funded_day":7,"investments":[{"company":{"name":"Sanofi Aventis","permalink":"sanofi-aventis-2","image":{"available_sizes":[[[150,119],"assets/images/resized/0005/4534/54534v3-max-150x150.png"],[[150,119],"assets/images/resized/0005/4534/54534v3-max-250x250.png"],[[150,119],"assets/images/resized/0005/4534/54534v3-max-450x450.png"]],"attribution":null}},"financial_org":null,"person":null}]},{"round_code":"unattributed","source_url":"http://www.masshightech.com/stories/2012/11/26/daily39-Rib-X-closes-first-tranche-of-675M-financing.html","source_description":"Rib-X closes first tranche of $67.5M financing","raised_amount":67500000,"raised_currency_code":"USD","funded_year":2012,"funded_month":11,"funded_day":29,"investments":[{"company":null,"financial_org":{"name":"Vatera Healthcare Partners","permalink":"vatera-healthcare-partners","image":null},"person":null},{"company":null,"financial_org":{"name":"Warburg Pincus","permalink":"warburg-pincus","image":{"available_sizes":[[[150,50],"assets/images/resized/0001/9008/19008v1-max-150x150.png"],[[250,83],"assets/images/resized/0001/9008/19008v1-max-250x250.png"],[[413,138],"assets/images/resized/0001/9008/19008v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"ABS Ventures","permalink":"abs-ventures","image":{"available_sizes":[[[150,57],"assets/images/resized/0001/0971/10971v1-max-150x150.jpg"],[[182,70],"assets/images/resized/0001/0971/10971v1-max-250x250.jpg"],[[182,70],"assets/images/resized/0001/0971/10971v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Vox Equity Partners I","permalink":"vox-equity-partners-i","image":null},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"Rib-X Pharmaceuticals","address1":"300 George Street  Suite 301","address2":"","zip_code":"06511-6663","city":"New Haven","state_code":"CT","country_code":"USA","latitude":41.305179,"longitude":-72.93117}],"milestones":[{"description":"has taken in a $20 million financing, led by Warburg Pincus LLC","stoned_year":2011,"stoned_month":1,"stoned_day":11,"source_url":"http://www.masshightech.com/stories/2011/01/10/daily16-Rib-X-raises-20M-to-develop-antibiotics.html","source_text":null,"source_description":"Rib-X raises $20M to develop antibiotics","stoneable_type":"Company","stoned_value":null,"stoned_value_type":null,"stoned_acquirer":null,"stoneable":{"name":"Rib-X Pharmaceuticals","permalink":"rib-x-pharmaceuticals"}},{"description":"has begun a Phase 2b clinical trial of its treatments for acute bacterial skin and skin structure infections","stoned_year":2011,"stoned_month":2,"stoned_day":8,"source_url":"http://www.masshightech.com/stories/2011/02/07/daily28-Rib-X-moves-skin-infection-treatment-to-Phase-2b-trial.html","source_text":null,"source_description":"Rib-X moves skin infection treatment to Phase 2b trial","stoneable_type":"Company","stoned_value":null,"stoned_value_type":null,"stoned_acquirer":null,"stoneable":{"name":"Rib-X Pharmaceuticals","permalink":"rib-x-pharmaceuticals"}}],"ipo":null,"video_embeds":[],"screenshots":[{"available_sizes":[[[150,95],"assets/images/resized/0004/3581/43581v1-max-150x150.jpg"],[[250,159],"assets/images/resized/0004/3581/43581v1-max-250x250.jpg"],[[450,286],"assets/images/resized/0004/3581/43581v1-max-450x450.jpg"]],"attribution":null}],"external_links":[]}